Here is why Johnson & Johnson (JNJ) stock faced instability on Thursday?

0
417
NTP Stock
NTP Stock

Johnson & Johnson’s (JNJ) shares plunged 1.74% in after-hours on Thursday, December 16, 2021, and moved at $170.00. However, in the regular trading session, JNJ’s stock gained 1.09%. JNJ shares have risen 15.59% over the last 12 months, and they have moved up 4.29% in the past week. Over the past three months, the stock has gained 5.01%, while over the past six months, it has gained 6.81%.

Let’s have a brief look at its recent news.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


CDC recommended Moderna and Pfizer vaccine over JNJ

Vaccine experts advising the Centers for Disease Control and Prevention voted unanimously to recommend Moderna and Pfizer’s messenger RNA-based Covid-19 vaccines over Johnson & Johnson’s jab.

The preference is given to Moderna and Pfizer after cases of a rare but serious blood clotting condition that has occurred in a small number of people who received the Johnson and Johnson vaccine.

EMA positive opinion about JNJ COVID-19 vaccine

 On December 15, 2021, Johnson & Johnson (JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine.

JNJ update about DARZALEX®

On December 11, 2021, Johnson & Johnson (JNJ) announced new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with 2  lenalidomide and dexamethasone (Rd). the new information came from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients and the data was presented at the American Society of Hematology (ASH) 2021 Annual Meeting.

Upcoming financial results announcement

 Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 25th to review fourth-quarter results. Joaquin Duato, incoming Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer, and Jessica Moore, Vice President, Investor Relations will host the call.

SAGE recommended the JNJ vaccine as a booster

On December 9, 2021, Johnson & Johnson’s (JNJ) announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above. The WHO recommends the booster shot should be administered two to six months after the primary vaccination.

Conclusion

It seems that Johnson & Johnson stock is facing fluctuation due to confusion about its covid -19 vaccine efficacy as a booster shot against the new variant known as Omicron. We can see it to perform well in the coming trading sessions.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here